Insider Transactions in Q1 2025 at Trevi Therapeutics, Inc. (TRVI)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2025
|
Thomas Sciascia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,631
-1.17%
|
$15,786
$6.6 P/Share
|
|
Mar 25
2025
|
Thomas Sciascia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,631
+1.16%
|
$2,631
$1.43 P/Share
|
|
Mar 21
2025
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
5,263
-2.41%
|
$31,578
$6.58 P/Share
|
|
Mar 21
2025
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,263
+2.35%
|
$5,263
$1.43 P/Share
|
|
Mar 10
2025
|
Farrell Simon Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
81,313
-27.0%
|
$487,878
$6.94 P/Share
|
|
Mar 10
2025
|
Farrell Simon Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
112,563
+23.88%
|
$225,126
$2.54 P/Share
|
|
Jan 08
2025
|
Lisa Delfini Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.18%
|
$0
$0.51 P/Share
|
|
Jan 07
2025
|
Lisa Delfini Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.65%
|
$0
$0.51 P/Share
|